Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...
Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for MiNK Therapeutics in a ...
MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic partnerships while navigating financial hurdles and leadership changes.
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant ...
MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe ...
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in invariant natural killer T (iNKT) cell therapies, announced its financial results for the fourth quarter and ...
MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) – Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of MiNK Therapeutics in a report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback